放疗联合GP方案治疗晚期非小细胞肺癌的临床研究

Radiotherapy and concurrent gemcitabinem plus cisplatinin on advanced non-small cell lung cancer

目的观察放疗联合国产吉西他滨和顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效及耐受性。方法选择42例晚期NSCLC患者,实施放疗联合GP方案治疗,放疗的剂量60～70Gy/6～7周,同时给予吉西他滨和顺铂化疗(GP方案)。结果全部患者均完成治疗,全部缓解(CR)6例,部分缓解(PR)28例,有效率为80.9%(CR+PR)。生存质量明显改善。不良反应主要为白细胞及血小板降低,但均能耐受。结论放疗联合吉西他滨和顺铂治疗晚期非小细胞肺癌近期疗效较好,能明显提高患者的生活质量,并且毒副反应大多数患者能耐受。

Objective To evaluate the effect and toxicity of radiotherapy and concurrent gemcitabinem plus cisplatinin for advanced non-small cell lung cancer （ NSCLC ）. Methods 42 patients with advanced NSCLC were selected,they were treated by radiotherapy with a total dose of DT60 - 70 Gy/6 -7weeks, and chemotherapy with gemcitabinem and cisplatin. Results 6 patients achieved complete remission （CR） and 28 partial remission（PR）. Total response rate was 80. 9 %. The main side effects were leucopenia and thrombocy- topenia, but they were tolerable. Conclusion The regimen of concurrent gemcitabinem plus cisplatinin and ra- diotherapy is effective, safe and well-tolerable in the treatment of for advanced NSCLC.